Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agenus Inc. stock logo
AGEN
Agenus
$5.93
+7.6%
$4.19
$1.38
$18.74
$166.42M1.51690,093 shs1.27 million shs
Compugen Ltd. stock logo
CGEN
Compugen
$1.78
+2.3%
$1.55
$1.13
$2.66
$157.06M2.57366,765 shs94,601 shs
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$4.38
+2.7%
$4.89
$3.61
$11.09
$48.12M1.43224,866 shs61,346 shs
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$0.30
$0.14
$0.01
$6.17
$541K0.966,759 shsN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$3.28
+2.5%
$3.22
$2.65
$9.55
$177.08M0.85481,444 shs303,242 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agenus Inc. stock logo
AGEN
Agenus
0.00%+24.58%+14.92%+280.13%-59.19%
Compugen Ltd. stock logo
CGEN
Compugen
0.00%+7.23%+4.09%+35.88%+6.59%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
0.00%+1.74%-14.72%-5.10%-52.86%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00%0.00%+500.00%-30.23%-92.06%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
0.00%+10.81%-0.61%+6.15%-57.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agenus Inc. stock logo
AGEN
Agenus
4.2707 of 5 stars
3.24.00.04.62.01.70.6
Compugen Ltd. stock logo
CGEN
Compugen
1.5607 of 5 stars
3.53.00.00.01.10.00.0
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
4.5769 of 5 stars
3.53.00.04.62.91.71.3
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/AN/AN/AN/AN/AN/AN/AN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.8429 of 5 stars
3.61.00.04.62.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agenus Inc. stock logo
AGEN
Agenus
2.33
Hold$14.00136.09% Upside
Compugen Ltd. stock logo
CGEN
Compugen
3.00
Buy$4.00124.72% Upside
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
3.00
Buy$47.00974.29% Upside
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00
N/AN/AN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.13
Buy$13.39308.23% Upside

Current Analyst Ratings Breakdown

Latest VYGR, TBIO, CGEN, AGEN, and DTIL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/4/2025
Agenus Inc. stock logo
AGEN
Agenus
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$4.00 ➝ $6.00
6/4/2025
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$25.00
5/21/2025
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
5/13/2025
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
5/13/2025
Agenus Inc. stock logo
AGEN
Agenus
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$3.00 ➝ $4.00
4/30/2025
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
4/21/2025
Agenus Inc. stock logo
AGEN
Agenus
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/8/2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agenus Inc. stock logo
AGEN
Agenus
$103.46M1.57N/AN/A($13.06) per share-0.45
Compugen Ltd. stock logo
CGEN
Compugen
$27.86M5.70N/AN/A$0.62 per share2.87
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$51.14M0.95N/AN/A$6.87 per share0.64
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$225.09M0.00N/AN/A$0.14 per share2.14
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$66.96M2.71N/AN/A$5.49 per share0.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agenus Inc. stock logo
AGEN
Agenus
-$227.21M-$8.67N/AN/AN/A-196.12%N/A-82.33%8/6/2025 (Estimated)
Compugen Ltd. stock logo
CGEN
Compugen
-$14.23M-$0.16N/AN/AN/A-51.27%-24.51%-12.19%8/5/2025 (Estimated)
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$7.17M-$2.01N/AN/AN/A-42.99%-69.26%-29.30%7/30/2025 (Estimated)
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
-$47.72M-$28.20N/AN/A-336.59%N/A-61.89%8/5/2025 (Estimated)
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$65M-$1.46N/AN/AN/A-126.49%-27.36%-21.06%8/5/2025 (Estimated)

Latest VYGR, TBIO, CGEN, AGEN, and DTIL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/19/2025Q1 2025
Compugen Ltd. stock logo
CGEN
Compugen
-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million
5/15/2025Q1 2025
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 million
5/12/2025Q1 2025
Agenus Inc. stock logo
AGEN
Agenus
-$1.61-$1.03+$0.58-$1.03$26.38 million$24.07 million
5/6/2025Q1 2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agenus Inc. stock logo
AGEN
Agenus
N/AN/AN/AN/AN/A
Compugen Ltd. stock logo
CGEN
Compugen
N/AN/AN/AN/AN/A
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
N/AN/AN/AN/AN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/AN/AN/AN/AN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agenus Inc. stock logo
AGEN
Agenus
N/A
0.11
0.11
Compugen Ltd. stock logo
CGEN
Compugen
N/A
5.09
5.09
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
0.45
6.62
6.62
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/A
1.23
1.06
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/A
6.10
6.10

Institutional Ownership

CompanyInstitutional Ownership
Agenus Inc. stock logo
AGEN
Agenus
61.46%
Compugen Ltd. stock logo
CGEN
Compugen
12.22%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
37.99%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
37.63%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
48.03%

Insider Ownership

CompanyInsider Ownership
Agenus Inc. stock logo
AGEN
Agenus
5.50%
Compugen Ltd. stock logo
CGEN
Compugen
9.50%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
4.50%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
24.50%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
6.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agenus Inc. stock logo
AGEN
Agenus
44027.42 million25.91 millionOptionable
Compugen Ltd. stock logo
CGEN
Compugen
7089.24 million80.76 millionOptionable
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
20011.09 million10.59 millionNo Data
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
2001.80 million1.36 millionOptionable
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
10055.34 million51.80 millionOptionable

Recent News About These Companies

Atlas Announces New Canadian Arctic Expedition Aboard World Voyager
VYGR Voyager Therapeutics, Inc. - Seeking Alpha
Voyager Technologies Soars with IPO Success
Voyager Technologies Shares Soar In Market Debut
Voyager raises $383 million from upsized IPO
Voyager Announces Pricing of Initial Public Offering
Brokers Issue Forecasts for VYGR FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Agenus stock logo

Agenus NASDAQ:AGEN

$5.93 +0.42 (+7.62%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$6.01 +0.08 (+1.35%)
As of 07/3/2025 04:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Compugen stock logo

Compugen NASDAQ:CGEN

$1.78 +0.04 (+2.30%)
Closing price 07/3/2025 02:20 PM Eastern
Extended Trading
$1.79 +0.01 (+0.51%)
As of 07/3/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Precision BioSciences stock logo

Precision BioSciences NASDAQ:DTIL

$4.38 +0.12 (+2.70%)
Closing price 07/3/2025 03:21 PM Eastern
Extended Trading
$4.36 -0.01 (-0.23%)
As of 07/3/2025 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Telesis Bio stock logo

Telesis Bio NASDAQ:TBIO

$0.30 0.00 (0.00%)
As of 07/3/2025

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Voyager Therapeutics stock logo

Voyager Therapeutics NASDAQ:VYGR

$3.28 +0.08 (+2.50%)
Closing price 07/3/2025 03:33 PM Eastern
Extended Trading
$3.20 -0.07 (-2.29%)
As of 07/3/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.